(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 15.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Day One Biopharmaceuticals's revenue in 2025 is $187,638,000.On average, 5 Wall Street analysts forecast DAWN's revenue for 2025 to be $14,787,483,576, with the lowest DAWN revenue forecast at $14,270,816,906, and the highest DAWN revenue forecast at $15,399,616,807. On average, 5 Wall Street analysts forecast DAWN's revenue for 2026 to be $20,737,549,700, with the lowest DAWN revenue forecast at $17,528,152,375, and the highest DAWN revenue forecast at $27,270,453,523.
In 2027, DAWN is forecast to generate $30,118,061,260 in revenue, with the lowest revenue forecast at $23,603,390,321 and the highest revenue forecast at $37,746,167,311.